Goodwin: The Destination Life Sciences M&A Firm
Deal News | Dec 06, 2024 | Goodwin
Goodwin has emerged as a dominant player in the life sciences mergers and acquisitions (M&A) sector, advising on a substantial number of diverse deals. Since Q3 2024, the firm has been at the forefront of M&A activities encompassing strategic sales, carveout deals, royalty acquisitions, reverse mergers, consolidations, and distressed transactions. Notable sell-side transactions include Biotheus's strategic partnership with BioNTech and Collegium's acquisition of Ironshore Therapeutics. On the buy-side, Ampersand Capital Partners completed its acquisition of Nektar Therapeutics' PEG Reagent Manufacturing Business, and Royalty Pharma engaged in multiple royalty acquisitions. Goodwin's strategic and commercial acumen is cemented by this diverse portfolio of M&A activities, solidifying its reputation as a top-tier global leader in the life sciences sector.
Sectors
- Life Sciences
- Mergers and Acquisitions
Geography
- Global – Goodwin operates on a global scale, and the transactions mentioned involve companies across various jurisdictions.
Industry
- Life Sciences – The article focuses on mergers and acquisitions activities specifically within the life sciences sector, showcasing the engagement of companies in this industry.
- Mergers and Acquisitions – The article primarily discusses a series of M&A transactions, emphasizing the role of Goodwin in facilitating these deals across sell-side and buy-side transactions.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Goodwin | Legal Advisor | Company | A global leader in mergers and acquisitions, providing strategic advice and execution in life sciences transactions. |
| Biotheus | Target Company | Company | Entered into a strategic partnership with BioNTech. |
| BioNTech | Bidding Company | Company | Engaged in a strategic partnership with Biotheus. |
| Collegium | Bidding Company | Company | Completed the acquisition of Ironshore Therapeutics. |
| Ironshore Therapeutics | Target Company | Company | Acquired by Collegium. |
| Ampersand Capital Partners | Bidding Company | Company | Completed acquisition of Nektar Therapeutics' PEG Reagent Manufacturing Business. |
| Royalty Pharma | Bidding Company | Company | Acquired royalty interest in Geron's Rytelo and entered a funding agreement with Ascendis Pharma. |
| Geron | Target Company | Company | Royalty interest in its product Rytelo was acquired by Royalty Pharma. |
| Ascendis Pharma | Target Company | Company | Entered into a royalty funding agreement with Royalty Pharma. |